DEF: MDB Capital Holdings Sets 2025 Annual Meeting Agenda

MDB Capital Holdings, LLC announces its 2025 Annual Meeting of Shareholders to be held virtually on December 2, 2025, to elect directors and ratify its independent accounting firm.

Summary

• The 2025 Annual Meeting of Shareholders will be held virtually on December 2, 2025, at 1:00 p.m. Eastern Time.
• Shareholders must register in advance at www.virtualshareholdermeeting.com/MDBH2025 prior to the deadline of 11:59 p.m. Eastern Time on December 1, 2025.
• Key proposals for the meeting include the election of seven director nominees and the ratification of RBSM LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
• The record date for voting is October 14, 2025, and proxy materials are expected to be mailed or made available on or about November 7, 2025.
• The company has 10,168,632 Class A and Class B shares outstanding as of the record date, with Class A shares having one vote and Class B shares having five votes, totaling 30,168,632 votes.
• MDB Capital Holdings is a 'controlled company' under Nasdaq listing rules, exempting it from certain corporate governance requirements, such as having a majority independent board or separate compensation and nominations committees.
• Executive compensation for 2024 included Christopher Marlett ($703,173), Mo Hayat ($1,133,078), and Anthony DiGiandomenico ($653,173).
• Related party transactions in 2024 included $1,485,822 paid to MDB Capital S.A., an entity owned by the CEO and Head of New Venture Discovery, and $41,400 in revenue from eXoZymes Inc., a company 47% owned by MDB Capital Holdings.

Sentiment

Score: 6

Explanation: The filing is a standard proxy statement for an annual meeting, outlining routine proposals for director elections and auditor ratification. It provides transparency on corporate governance, executive compensation, and related party transactions. The 'controlled company' status, while disclosed, means fewer independent oversight mechanisms compared to non-controlled public companies, which could be a point of concern for some investors. However, the presence of an independent audit committee and specific policies like clawback and insider trading are positive governance aspects.

Positives

• An independent audit committee is established, with Daniel Torpey serving as a qualified financial expert and chair, ensuring robust financial oversight.
• A clawback policy is in place to recover excess compensation based on restated financial reporting measures, enhancing executive accountability.
• An insider trading compliance policy, including black-out periods and pre-clearance requirements, is adopted to promote adherence to securities laws.
• The company provides indemnification to directors and officers and maintains insurance to protect against expenses and liabilities.
• The 2022 Equity Incentive Award Plan is designed to align the personal and financial interests of management and employees with long-term shareholder success.

Negatives

• MDB Capital Holdings is classified as a 'controlled company' under Nasdaq rules, which exempts it from certain corporate governance requirements, such as having a majority independent board or separate compensation and nominations committees.
• Shareholders will not have the same corporate governance protections afforded to shareholders of companies that are subject to all Nasdaq requirements.
• The Board does not have a formal policy regarding the separation of the roles of Chief Executive Officer and Chairperson, with Christopher Marlett holding both positions, which could concentrate power.
• Significant related party transactions exist, including $1,485,822 paid to MDB Capital S.A. in 2024, an entity owned by the CEO and Head of New Venture Discovery, which may present potential conflicts of interest.

Risks

• The 'controlled company' status means the company is exempt from certain Nasdaq listing requirements, potentially leading to less independent oversight compared to other public companies.
• The concentration of voting power (approximately 85%) in Class B shares held by two individuals (Christopher Marlett and Anthony DiGiandomenico) could limit the influence of other shareholders on corporate decisions.
• The absence of a formal policy separating the roles of CEO and Chairman, with Christopher Marlett holding both, could concentrate power and potentially reduce independent board oversight.
• Reliance on related party transactions, such as services from MDB Capital S.A., could present potential conflicts of interest, despite the audit committee's review process.

Future Outlook

The company plans to hold its 2026 annual meeting in June 2026 and has outlined deadlines for shareholder proposals and director nominations for that meeting. The equity incentive plan is designed to provide long-term incentives and align management interests with shareholder value, with awards dependent on increases in Class A Common Share price.

Management Comments

• We cordially invite you to attend the 2025 annual meeting of shareholders.
• Our Board believes that our shareholders are best served at this time by having a Chairperson who is an integral part of our Board structure and a critical aspect of effective corporate governance.
• Management intends to take advantage of these exemptions [as a controlled company] as long as it is a controlled company.
• We are committed to ensuring, to the extent possible, that shareholders will be given the same participation rights that they would be given if they attended an in-person meeting.

Industry Context

As a publicly traded company, MDB Capital Holdings operates within the highly regulated financial services industry, where corporate governance and transparency are paramount. Its 'controlled company' status, while permissible under Nasdaq rules, deviates from the broader trend towards enhanced independent board oversight and shareholder protections seen in many industry peers. The company's focus on venture-stage public companies and technology commercialization positions it within the innovation financing segment, where aligning management incentives with long-term shareholder value is critical, as reflected in its equity incentive plan.

Comparison to Industry Standards

• The company's 'controlled company' status, with approximately 85% of voting power concentrated in two individuals, deviates significantly from the standard corporate governance practice of most publicly traded companies, which typically aim for a majority independent board and separate compensation/nominations committees, unlike companies such as Apple (AAPL) or Microsoft (MSFT) that maintain robust independent board structures.
• The combined role of CEO and Chairman (Christopher Marlett) is less common among large-cap companies, where separation is often preferred to enhance independent oversight, as seen in companies like JPMorgan Chase (JPM) or Bank of America (BAC) which often have independent chairmen.
• The audit committee, composed entirely of independent directors and chaired by a financial expert (Daniel Torpey), aligns with best practices and SEC/Nasdaq requirements for audit functions, similar to the standards upheld by major financial institutions.
• The existence of a clawback policy and insider trading policy demonstrates adherence to modern corporate governance principles aimed at financial integrity and preventing market abuse, comparable to policies at most established public companies.
• The significant related party transactions, such as payments to MDB Capital S.A. and dealings with eXoZymes Inc. and ENDRA Life Sciences Inc., while reviewed by the audit committee, warrant closer scrutiny compared to companies with fewer or no such transactions, where potential conflicts of interest are minimized.

Management Changes

Corporate Governance

Related Party Transactions

• Payments to MDB Capital S.A., an entity owned by Christopher Marlett (CEO) and Anthony DiGiandomenico (Head of New Venture Discovery), for services: $1,485,822 in 2024 and $1,123,401 in 2023.
• PatentVest (100% owned by MDB Capital Holdings) engaged in transactions with ENDRA Life Sciences Inc., where Anthony DiGiandomenico serves as a board member; no revenue recognized in 2024, but $80,995 in costs incurred.
• PatentVest engaged in transactions with eXoZymes Inc., a company in which MDB Capital Holdings owns 47%, recognizing revenues of $41,400 in 2024.
• Accrued receivables in 2024 totaling $63,759, including $41,400 from eXoZymes Inc. and $22,359 for taxes paid on behalf of officers (reimbursed by January 31, 2025).
• Accrued expenses of $22,842 payable to officers and directors for reimbursable expenses in 2024.
• All related party transactions are stated to be conducted on an arms-length basis and reviewed by the audit committee.

Stakeholder Impact

• Shareholders: Will vote on key governance matters (director election, auditor ratification). Class B shareholders (Christopher Marlett and Anthony DiGiandomenico) retain significant voting control (approximately 85%), potentially limiting influence for Class A shareholders. The 'controlled company' status means fewer independent board protections.
• Employees: Subject to an insider trading policy and potentially benefit from the equity incentive plan. Executive officers are subject to a clawback policy.
• Customers/Suppliers: Not directly impacted by this proxy statement, but the company's governance structure and financial health (as implied by audit and related party disclosures) could indirectly affect long-term relationships.
• Creditors: The financial disclosures and governance structure provide insight into the company's stability and risk management, which is relevant for assessing creditworthiness.
• Management/Directors: Subject to specific compensation structures, equity awards, and governance policies, including indemnification and liability limitations.

Next Steps

• Shareholders are to vote on the election of seven director nominees at the Annual Meeting.
• Shareholders are to vote on the ratification of RBSM LLP as the independent registered public accounting firm for fiscal year 2025.
• The company will announce preliminary voting results at the Annual Meeting and file a Current Report on Form 8-K with final results within four business days.
• Shareholders interested in proposing actions or nominating directors for the 2026 annual meeting must submit proposals by specific deadlines (February 1, 2026, for inclusion in proxy statement; February 1 March 1, 2026, for other proposals).

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting, not a financial results announcement or a significant strategic update. It provides transparency on corporate governance, executive compensation, and related party transactions. While the 'controlled company' status presents some governance considerations, the company has an independent audit committee and robust policies for insider trading and compensation clawbacks. There are no immediate catalysts or red flags that would warrant a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and monitor future financial performance and strategic developments.

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, SEC Filing, MDB Capital Holdings, Controlled Company, Executive Compensation, Related Party Transactions, Shareholder Voting, Nasdaq Exemptions